DOI: 10.1097/ju9.0000000000000138 ISSN: 2771-554X

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

Alan H. Bryce, E. David Crawford, Neeraj Agarwal, Maha H. Hussain, Himisha Beltran, Matthew R. Cooperberg, Daniel P. Petrylak, Neal Shore, Daniel E. Spratt, Scott T. Tagawa, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Thomas P. Boike, Jeremie Calais, Michael A. Carducci, Brian F. Chapin, Michael S. Cookson, John W. Davis, Tanya Dorff, Scott E. Eggener, Felix Y. Feng, Martin Gleave, Celestia Higano, Andrei Iagaru, Alicia K. Morgans, Michael Morris, Katie S. Murray, Wendy Poage, Matthew B. Rettig, Oliver Sartor, Howard I. Scher, Paul Sieber, Eric Small, Sandy Srinivas, Evan Y. Yu, Tian Zhang, Phillip J. Koo
Show PDF Cite

Background:

Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature.

Materials and Methods:

The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators.

Results:

This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)–positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies.

Conclusions:

The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.

More from our Archive